Affordable Access

deepdyve-link
Publisher Website

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Authors
  • Arnold, Michael B1
  • Khanna, Dinesh2
  • Denton, Christopher P3
  • van Laar, Jacob M4
  • Frech, Tracy M5
  • Anderson, Marina E6
  • Baron, Murray7
  • Chung, Lorinda8
  • Fierlbeck, Gerhard9
  • Lakshminarayanan, Santhanam10
  • Allanore, Yannick11
  • Riemekasten, Gabriela12
  • Steen, Virginia13
  • Müller-Ladner, Ulf14
  • Spotswood, Helen15
  • Burke, Laura15
  • Siegel, Jeffrey16
  • Jahreis, Angelika16
  • Furst, Daniel E17
  • Pope, Janet E1
  • 1 Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. , (Canada)
  • 2 Rheumatology, University of Michigan Scleroderma Program, Ann Arbor, MI, USA.
  • 3 Rheumatology and Connective Tissue Diseases, University College London Medical School, London, UK.
  • 4 Rheumatology & Clinical Immunology, University of Utrecht, Utrecht, The Netherlands. , (Netherlands)
  • 5 Rheumatology, University of Utah, Veterans Affairs Medical Center, Salt Lake City, UT, USA.
  • 6 Rheumatology, University of Liverpool and Aintree University Hospital, Liverpool, UK.
  • 7 Rheumatology, Jewish General Hospital, Montreal, QC, Canada. , (Canada)
  • 8 Medicine and Dermatology, Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, USA.
  • 9 Dermatology, University of Tubingen, Tubingen, Germany. , (Germany)
  • 10 Rheumatology, University of Connecticut Health Center, Farmington, CT, USA.
  • 11 Rheumatology, Paris Descartes University, Paris, France. , (France)
  • 12 Rheumatology, Charité University Hospital, German Rheumatism Research Center, Berlin, Germany. , (Germany)
  • 13 Rheumatology, Georgetown University, Washington, DC, USA.
  • 14 Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie, Justus-Liebig University Giessen, Kerckhoff Clinic, Bad Nauheim, Germany. , (Germany)
  • 15 Roche Products Ltd, Welwyn Garden City, UK.
  • 16 Rheumatology and Rare Diseases, Genentech, South San Francisco.
  • 17 Rheumatology, University of California, Los Angeles, CA, USA.
Type
Published Article
Journal
Rheumatology (Oxford, England)
Publication Date
Jan 01, 2018
Volume
57
Issue
1
Pages
152–157
Identifiers
DOI: 10.1093/rheumatology/kex396
PMID: 29077900
Source
Medline
Keywords
License
Unknown

Abstract

PASS may be used as a patient-centred outcome in SSc, especially as a 7-point Likert scale. Further validation is required to determine the utility as an outcome measure in trials and clinical practice.

Report this publication

Statistics

Seen <100 times